Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer characterized by an unfavorable prognosis due to its aggressive biology. The median overall survival (OS) for patients with metastatic TNBC is around 9–12 months with conventional cytotoxic agents. Considering this suboptimal outcome, which is induced despite of medical treatment, new therapeutic strategies would be urgently needed. The ultimate goal of precision medicine is to identify specific molecular alterations that permit considering effective targeted drug(s). Germline BRCA mutations occur in 10–20% of TNBC patients while somatic mutations occur in 3–5% of them. Alterations in the homologous recombination (HR) system are typical of BRCA mutant tumors, but can also be identified in tumors that do not carry this mutation, defining a subgroup of patients referred to as BRCAness. In this review, we focus on the role of homologous recombination deficiency (HRD) as both predictive and prognostic factor in different settings of TNBC patients treated with DNA damaging drugs and poly ADP ribose polymerase (PARP) inhibitors.
Homologous recombination deficiency in triple negative breast cancer / C. Belli, B. Achutti Duso, E. Ferraro, G. Curigliano. - In: THE BREAST. - ISSN 0960-9776. - 45(2019 Jun), pp. 15-21.
|Titolo:||Homologous recombination deficiency in triple negative breast cancer|
|Parole Chiave:||BRCA mutations; Homologous recombination deficiency; PARP inhibitors; Platinum agent; Triple negative breast cancer; Surgery|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||giu-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.breast.2019.02.007|
|Appare nelle tipologie:||01 - Articolo su periodico|